Yescarta (axicabtagene ciloleucel) — HCPCS Q2041

About Yescarta (axicabtagene ciloleucel)

Yescarta is the brand name for axicabtagene ciloleucel (axi-cel), an autologous chimeric antigen receptor (CAR) T-cell immunotherapy directed against the CD19 antigen, manufactured by Kite Pharma, a Gilead Sciences company. It is the second FDA-approved CAR-T cell therapy (October 18, 2017, six weeks after Kymriah) and the first CAR-T approved in the 2L LBCL setting based on the practice-changing ZUMA-7 trial (April 1, 2022). Each Yescarta dose is a patient-specific cellular product: the patient's own T cells are collected by leukapheresis, shipped to the Kite manufacturing facility, genetically modified to express the anti-CD19 CAR construct with a CD28 costimulatory domain, expanded, cryopreserved, and shipped back to the certified treatment center for infusion. Yescarta's vein-to-vein time is approximately 14-17 days, one of the fastest in the CAR-T class.

Yescarta carries three FDA-approved indications:

• Adult relapsed/refractory large B-cell lymphoma (3L+) after at least two prior lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma — approved October 18, 2017 based on the ZUMA-1 trial.
• Relapsed/refractory follicular lymphoma (FL) after at least two prior lines of systemic therapy — accelerated approval March 5, 2021 based on the ZUMA-5 trial.
• Adult relapsed/refractory large B-cell lymphoma in the second-line setting — primary refractory or relapse within 12 months of first-line chemoimmunotherapy — approved April 1, 2022 based on the ZUMA-7 trial. This was the first CAR-T approved at 2L and remains the dominant data-driven positioning argument vs Kymriah and Breyanzi.

Yescarta is billed under HCPCS Q2041 as a single therapeutic dose. The HCPCS descriptor explicitly bundles the leukapheresis and dose preparation procedures into the Q-code, though most payers and CMS still permit separate billing of the apheresis CPT and lymphodepletion drugs in practice. Administration is restricted to FACT-accredited centers certified under the YESCARTA REMS program. Approximate list price (single dose): ~$424,000 USD.

CD19 CAR-T class — Yescarta vs Kymriah vs Tecartus vs Breyanzi FDA + payer review May 2026

Four anti-CD19 CAR-T products exist, plus two BCMA-targeted CAR-T products for myeloma. Coding and PA logic are not interchangeable.

The 5-stage CAR-T workflow FDA label + REMS verified May 2026

CAR-T billing is fundamentally different from standard drug billing because the encounter spans 4-6 weeks across multiple claims.

Typical claim cadence

1. Claim A — Apheresis encounter: CMS-1500 or UB-04 with 38206 (or 0540T) + supporting ICD-10. Often paid as outpatient hospital service or office procedure.
2. Claim B — Lymphodepletion encounter(s): J9185 + J9070 with admin CPTs 96409/96413/96415 as appropriate. May span 3 outpatient visits or one short admission.
3. Claim C — CAR-T admission: UB-04 inpatient with ICD-10-PCS procedure (XW033C3 or XW043C3) driving MS-DRG 018. Q2041 line-item is included in the DRG bundle. Or, in outpatient infusion path, UB-04 outpatient with APC payment + Q2041 + 0537T-0541T line items.
4. Claim D — CRS/ICANS readmission (if applicable): Inpatient DRG based on principal manifestation (sepsis, respiratory failure, encephalopathy) with tocilizumab and supportive care billed within the DRG.

Dosing & cellular dose math FDA label verified May 2026

Yescarta is one therapeutic dose, calculated to a target 2 x 10^6 CAR-positive viable T cells per kg, capped at 2 x 10^8 total.

Lymphodepletion dosing (Stage 3)

Per the FDA label, lymphodepletion is administered days -5 through -3 prior to Yescarta infusion. The Yescarta label regimen is fludarabine 30 mg/m^2 IV daily x 3 days (J9185) plus cyclophosphamide 500 mg/m^2 IV daily x 3 days (J9070) — identical for all three Yescarta indications. Each chemotherapy agent and each administration day generates a separate billable line.

NDC reference FDA NDC Directory + Kite verified May 2026

Yescarta uses a patient-specific NDC pattern - every patient's dose is uniquely identified by lot.

YESCARTA REMS + FACT accreditation Kite + FACT verified May 2026

Yescarta is available only through a restricted REMS program because of the boxed warnings for CRS and neurologic toxicity.

The YESCARTA REMS is administered by Kite Pharma and operates as closed distribution. Three certification layers must all be in place:

• Facility certification (Kite Authorized Treatment Center): the hospital or cellular therapy center must be on the Kite-maintained list of authorized Yescarta Treatment Centers. Certification requires FACT or FACT-JACIE accreditation for cellular therapy, demonstrated capacity to recognize and manage CRS and ICANS (with particular attention to Yescarta's elevated CRS Grade 3+ rate), immediate availability of tocilizumab (Actemra) for IV use (minimum 2 doses on hand per certified site), and qualified ICU backup.
• Healthcare provider certification: prescribing physicians must complete the YESCARTA REMS training and be enrolled.
• Pharmacy / chain-of-custody certification: the receiving pharmacy and cellular therapy lab must verify physician + facility certification before accepting the patient-specific cellular product.

How to enroll / verify

• Web: Kite maintains the YESCARTA REMS portal — check the most recent Yescarta Prescribing Information for the current REMS URL and contact. Kite Konnect (the patient hub) can route facility questions to the REMS team.
• FACT accreditation: factwebsite.org — verify accreditation status of any center before referral.
• Documentation: retain REMS enrollment confirmation in the patient chart and on every PA submission. Submit FACT accreditation certificate as a PA attachment.

Administration codes — the multi-stage code set CPT 2026 verified May 2026

Each of the 5 stages has its own administration code family. Map them to the correct claim.

Stage 1 - Apheresis

Stage 3 - Lymphodepletion (chemo admin)

Stage 4 - CAR-T infusion administration set

Stage 5 - CRS / ICANS management

Tocilizumab (Actemra, HCPCS J3262) is the FDA-approved CRS treatment. Dose for CRS: 8 mg/kg IV (max 800 mg), up to 4 doses. Bill J3262 with appropriate IV infusion admin code (96365). When CRS occurs during the inpatient CAR-T admission, tocilizumab is bundled in MS-DRG 018; when administered outpatient or during a separate readmission, bill J3262 line-item against the relevant ICD-10 (D89.83x for CRS - see ICD-10 section). Yescarta's higher CRS Grade 3+ rate means toci utilization is operationally higher than with Kymriah or Breyanzi — pharmacy preparation protocols should reflect this.

Modifiers CMS + CPT verified May 2026

Modifiers rarely apply to Q2041 itself

Unlike weight-based drug J-codes, the single-dose Q2041 code does not generate JW (drug waste) or JZ (no-waste single-dose container) reporting in most circumstances. The cellular product is one patient-specific infusion bag - it is either administered in its entirety to the labeled patient or the manufacturing fails and the product is not infused (in which case Q2041 is not billed). There is no partial-vial waste scenario analogous to small-molecule oncology drugs.

Modifier 25 - same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as a CAR-T-related procedure. Pre-infusion clinical assessment is bundled; a same-day workup for a new complication is separately reportable with 25.

340B modifiers (JG, TB)

Most CAR-T treatment centers are 340B-covered entities. For 340B-acquired Q2041, follow your MAC's current 340B modifier policy (JG or TB as required). Kite CAR-T discount and 340B interaction with the OPPS/IPPS payment is jurisdiction-specific - verify with your 340B compliance team.

Modifiers on lymphodepletion (Stage 3)

Lymphodepletion uses standard chemotherapy modifier rules - JW on partial-vial waste for fludarabine and cyclophosphamide as needed; JZ when no waste. These follow the standard J9185 and J9070 modifier logic and are unrelated to Q2041 billing.

ICD-10-CM & ICD-10-PCS coding FY2026 verified May 2026

Two coding systems matter: ICD-10-CM for diagnosis (every claim), ICD-10-PCS for the CAR-T procedure (inpatient only - drives MS-DRG 018).

ICD-10-CM diagnoses

ICD-10-PCS procedures (inpatient claims)

Site of care, place of service & DRG/APC mapping FY 2026 IPPS/OPPS verified May 2026

Inpatient FACT-accredited centers remain the dominant CAR-T setting; outpatient infusion is rising at qualifying centers.

MS-DRG 018 details

Effective FY 2021, CMS introduced MS-DRG 018 - "Chimeric Antigen Receptor (CAR) T-cell Immunotherapy" as a dedicated CAR-T DRG. Before FY 2021, CAR-T admissions defaulted to MS-DRG 016 (Autologous Bone Marrow Transplant w/ CC/MCC) which significantly under-reimbursed the cellular product cost. MS-DRG 018 is assigned when the ICD-10-PCS principal procedure is XW033C3, XW043C3, or a related new-technology code for autologous CAR-T administration. The relative weight for MS-DRG 018 is among the highest in the IPPS to reflect the ~$424K-650K cell product acquisition cost; the actual hospital payment under MS-DRG 018 still typically falls short of total acquisition cost in many cases.

Outpatient CAR-T - APC payment

Where commercial payers (or select Medicare Advantage plans) require outpatient CAR-T infusion at a qualifying outpatient cellular therapy center, payment runs through OPPS. CMS established a CAR-T outpatient APC pathway; the specific APC number is updated annually in the OPPS Final Rule (APC 9248 has been used historically; verify the current rule). Outpatient billing reports Q2041 as a separately payable line item plus the 0537T-0540T administration set. If CRS develops within 7-30 days, admit to inpatient under a CRS-driven DRG (not back into MS-DRG 018).

Claim form field mapping - 4 claims, one encounter Kite + CMS verified May 2026

The CAR-T encounter spans 4 separate claims. Each has its own form, fields, and PA reference.

Claim A — Apheresis (Stage 1)

Claim B — Lymphodepletion (Stage 3)

Claim C — CAR-T infusion (Stage 4)

Claim D — CRS / ICANS readmission (Stage 5, if applicable)

Payer policy snapshot Reviewed May 2026

All major payers require PA, FACT documentation, REMS enrollment confirmation, prior therapy lines, and ECOG performance status.

NCCN Guidelines

NCCN B-Cell Lymphomas Guidelines (current version) include axicabtagene ciloleucel as a Category 1 recommendation for the 2L LBCL indication (post-ZUMA-7) and Category 2A for 3L+ DLBCL and R/R FL. NCCN compendium support strengthens 2L coverage arguments and bridges any payer-policy lag for newer indications like ZUMA-5 FL.

Required PA documentation checklist

• FACT (or FACT-JACIE) accreditation certificate for the treatment center
• YESCARTA REMS certification letter for the prescribing physician and the facility
• Prior therapy log: each regimen, dates, response, reason for discontinuation
• For 2L LBCL: explicit documentation of "primary refractory" or "relapse within 12 months of first-line chemoimmunotherapy completion" (the ZUMA-7 eligibility gate)
• ECOG performance status (most policies require 0-2)
• Diagnostic pathology confirming CD19+ disease (for DLBCL/LBCL/FL)
• Imaging / disease burden assessment within recent window (per payer policy, often 30-60 days)
• CNS disease exclusion documentation (CNS-2/3 active disease is typically excluded for LBCL CAR-T)
• Cardiac and pulmonary clearance (LVEF, pulmonary function tests as required)
• Absence of active autoimmune disease requiring systemic immunosuppression

Medicare reimbursement CMS Q2 2026 (live)

Q2041 has a quarterly ASP payment limit; MS-DRG 018 sets the inpatient DRG payment; OPPS APC handles outpatient.

MS-DRG 018 - CAR-T Immunotherapy

Inpatient CAR-T admissions are reimbursed under MS-DRG 018, introduced in FY 2021. The DRG weight is set annually in the IPPS Final Rule and reflects the high cellular product acquisition cost. Despite MS-DRG 018's elevated weight, most hospitals report DRG 018 payment falls short of the total acquisition + admission cost in a material proportion of cases. ICD-10-PCS principal procedure XW033C3 (or XW043C3) drives the DRG assignment.

NTAP history

• FY 2019 - FY 2021: Yescarta received CMS NTAP add-on payment, recognizing the gap between historical DRG payment and acquisition cost.
• FY 2021 onward: NTAP for axicabtagene ciloleucel expired after the standard 3-year window. CMS replaced NTAP-and-old-DRG with the new MS-DRG 018 to set a permanent CAR-T-appropriate DRG.
• Verify each FY: CMS occasionally extends or revises CAR-T add-on policy through the IPPS Final Rule. Confirm in the current Final Rule before assuming or disclaiming NTAP. Newer CAR-T indications (e.g., the 2022 2L ZUMA-7 approval) did not separately trigger new NTAP; the existing MS-DRG 018 covers all autologous CAR-T regardless of line of therapy.

Outpatient OPPS APC

Outpatient CAR-T infusion (Stage 4 in the outpatient pathway) is paid under OPPS through a CAR-T-specific APC. APC 9248 has historically been used for CAR-T cell therapy; CMS updates the precise APC and rate annually in the OPPS Final Rule. Q2041 is paid separately under OPPS when the infusion is outpatient (it is not packaged into the APC). Always verify the current OPPS Addendum B for the precise APC assignment.

Coverage

Medicare coverage of CAR-T is governed by NCD 110.24 (Chimeric Antigen Receptor T-cell Therapy). The NCD covers FDA-approved autologous CAR-T for FDA-approved indications administered at a facility enrolled in the FDA-required REMS program and with FACT (or equivalent) accreditation. Coverage with Evidence Development requirements (CED) sunset in 2022; standard coverage applies. Yescarta's 2022 2L LBCL approval (ZUMA-7) is covered under the same NCD without a separate coverage decision.

Patient assistance — Kite Konnect Kite verified May 2026

• Kite Konnect: Kite-administered patient hub for Yescarta and Tecartus — benefits investigation, prior authorization assistance, appeal support, copay support (commercial-only), case-management through the multi-stage CAR-T encounter. Confirm the current phone and portal URL on the most recent Yescarta Patient Brochure shipped with the cellular product.
• Gilead Advancing Access (PAP): Kite is a Gilead subsidiary; the Gilead Advancing Access Patient Assistance Program offers free product pathway for eligible uninsured and underinsured patients meeting federal poverty level (typically 500% FPL income threshold for oncology products; verify current). Application via the patient's CAR-T case manager. gileadadvancingaccess.com
• Independent foundations (Medicare-eligible): for Medicare patients facing affordability gaps on lymphodepletion drugs, monitoring, and travel costs - refer to Patient Access Network Foundation (PAN), HealthWell Foundation, and CancerCare. Verify open DLBCL/LBCL and FL funds quarterly.
• Travel and lodging: Yescarta is administered only at FACT-certified centers, often requiring travel. Kite Konnect and many treatment centers maintain travel grants for patients living > 50-100 miles from a treatment center.

Common denials & how to fix them

Frequently asked questions

What is the HCPCS code for Yescarta?

Yescarta (axicabtagene ciloleucel) is billed under HCPCS Q2041 — "Axicabtagene ciloleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose." The unit basis is one therapeutic dose per single IV infusion. The descriptor explicitly bundles leukapheresis and dose preparation, though most payers and CMS still permit separate billing of apheresis CPT and lymphodepletion drugs.

How is Yescarta different from Kymriah?

Both are autologous anti-CD19 CAR-T products, but they are distinct biologics with their own HCPCS codes, REMS programs, and FACT certifications. Yescarta (axi-cel, Q2041, Kite/Gilead) uses a CD28 costimulatory domain; Kymriah (tisa-cel, Q2042, Novartis) uses 4-1BB. Yescarta has a faster manufacturing turnaround (~14-17 days vs ~3-4 weeks for Kymriah), is approved at 2L LBCL (ZUMA-7) where Kymriah is not, and is NOT approved in pediatric/young adult ALL (which Kymriah is). Yescarta has a higher CRS Grade 3+ rate (~13-25%) and higher ICANS rate than Kymriah, attributable to the CD28 costimulatory design. Patient support is through Kite Konnect (not Kymriah Cares).

What does ZUMA-7 mean for Yescarta billing?

ZUMA-7 (NEJM 2022) established Yescarta as superior to standard-of-care chemoimmunotherapy + autologous HSCT in primary refractory or early-relapsing (within 12 months of first-line) LBCL. FDA approved Yescarta for 2L LBCL on April 1, 2022. For PA, a patient with primary refractory or early-relapsing LBCL can receive Yescarta after only ONE prior line of therapy. The PA must document the timing of relapse explicitly: "primary refractory" or "relapse within 12 months of first-line chemoimmunotherapy." Missing this timing detail is the #1 PA error in 2L Yescarta cases.

What is the multi-stage CAR-T billing workflow for Yescarta?

Five stages: (1) Apheresis — CPT 38206 or 0540T at a FACT-accredited center; (2) Manufacturing wait of approximately 14-17 days (fastest in CAR-T class) with no billing; (3) Lymphodepletion with fludarabine (J9185) and cyclophosphamide (J9070), typically days -5 to -3; (4) CAR-T infusion — Q2041 single dose plus the 0537T-0541T administration set; (5) CRS/ICANS monitoring and any 30-day readmission management. Stages 3-5 most often combine into one inpatient admission billed under MS-DRG 018.

What are MS-DRG 016 and 018 for CAR-T?

Effective FY 2021 CMS created MS-DRG 018 ("Chimeric Antigen Receptor (CAR) T-cell Immunotherapy") as the dedicated CAR-T DRG. MS-DRG 018 is assigned when the ICD-10-PCS principal procedure is XW033C3 / XW043C3 or related CAR-T new-tech codes. MS-DRG 016 covers some autologous bone marrow transplant cases - it is not the right CAR-T DRG. If your encoder is sending a CAR-T case to 016 instead of 018, the issue is usually a missing or out-of-version PCS code or an outdated grouper.

Does Yescarta have NTAP add-on payment status?

Yescarta received CMS NTAP starting FY 2019; NTAP for axicabtagene ciloleucel expired after FY 2021 and CAR-T was reclassified into the new MS-DRG 018. Yescarta inpatient admissions are now reimbursed under MS-DRG 018 alone, without separate NTAP. The April 2022 2L ZUMA-7 approval did not trigger new NTAP. Verify each FY IPPS Final Rule because CMS occasionally extends or revises CAR-T add-on policy.

What FACT accreditation is required?

Yescarta may only be administered at healthcare facilities certified through the YESCARTA REMS, which requires FACT (or FACT-JACIE) accreditation for cellular therapy plus on-site CRS/ICANS management capability, immediate tocilizumab availability, and ICU backup. Kite maintains the list of certified treatment centers. A center may be FACT-accredited and Kymriah-certified but NOT Yescarta-certified — each manufacturer's REMS is separately administered. Confirm Kite Yescarta certification BEFORE Stage 1.

Outpatient vs inpatient CAR-T - which setting do I bill?

Historically Yescarta was almost always inpatient under MS-DRG 018. Since 2023 some commercial payers and select Medicare Advantage plans require outpatient CAR-T infusion at qualifying outpatient cellular therapy centers when CRS risk is low. For Yescarta specifically, payer outpatient steering is more cautious due to the elevated CRS Grade 3+ rate; many payers default outpatient pathway to Breyanzi or Kymriah while keeping Yescarta inpatient. Outpatient billing reports Q2041 as a separately payable line under OPPS (APC 9248 historically) plus the 0537T-0540T administration codes. Always verify the payer's site-of-service requirement before scheduling.

What apheresis CPT do I bill for Yescarta - 38205, 38206, or 0540T?

38206 (autologous hematopoietic harvesting) has historically been the most common code for CAR-T leukapheresis. 38205 is allogeneic and does not apply to autologous CAR-T. 0540T is a Category III code specific to CAR-T-associated apheresis service. Payer acceptance varies - most MACs accept 38206; some commercial payers require 0540T. Confirm per-payer before submission.

What are the CAR-T infusion administration codes (0537T family)?

The Category III CAR-T administration set: 0537T (harvesting / planning), 0538T (preparation for transportation), 0539T (receipt and prep for administration), 0540T (CAR-T cell administration), and 0541T (preparation of CAR-T product). Standard IV infusion codes (96365, 96413) are not appropriate substitutes - CAR-T cellular product infusion is a distinct service.

How is CRS readmission after Yescarta billed?

If the patient is infused outpatient and develops Grade 2+ CRS or ICANS requiring inpatient admission within 30 days, the readmission is billed under the inpatient DRG for the principal manifestation (sepsis, respiratory failure, encephalopathy) with D89.83x (CRS) and G92.0x (ICANS) as secondary diagnoses. Tocilizumab (J3262) is billable inpatient bundled in DRG; outpatient is line-item billable. Yescarta's higher CRS rate (78-93% any-grade, 13-25% Grade 3+) makes this readmission pathway operationally common. Some payers maintain CAR-T bundled-payment arrangements that include all 30-day post-infusion care - check the contract.

What happens if Yescarta manufacturing fails - is re-collection billable?

Yescarta's manufacturing failure rate is low (~2-4%, lower than Kymriah's historical 7-10%), and Kite policy historically provides manufacturing-failure replacement at no additional drug cost — verify the current Kite policy through Kite Konnect. The repeat apheresis (38206 or 0540T) is generally separately billable; document the manufacturing failure with the Kite case manager and submit a fresh PA referencing the prior approval. Some payers require a new PA cycle; others amend the existing authorization.

Source documents

1. Yescarta HCP page (Kite Pharma / Gilead)
   Manufacturer dosing, REMS, treatment center locator, and Kite Konnect patient support reference
2. DailyMed — YESCARTA (axicabtagene ciloleucel) Prescribing Information
   FDA-approved label, revision February 12, 2026 (BLA 125643, Kite Pharma, Inc. / Gilead). Three boxed warnings: CRS, neurologic toxicities/ICANS, T-cell malignancies.
3. FDA Approval Announcement — Axicabtagene Ciloleucel (Oct 18, 2017)
   Second FDA-approved CAR-T cell therapy
4. FDA Approval — Yescarta 2L LBCL (April 1, 2022, ZUMA-7)
   First CAR-T approval at second-line
5. Neelapu SS et al. - ZUMA-1 trial (3L+ DLBCL), NEJM 2017
6. Jacobson CA et al. - ZUMA-5 trial (R/R FL), Lancet Oncology 2022
7. Locke FL et al. - ZUMA-7 trial (2L LBCL), NEJM 2022
   Practice-changing 2L LBCL data — basis of April 2022 FDA approval
8. FACT (Foundation for the Accreditation of Cellular Therapy)
   Accreditation standards for cellular therapy programs (FACT and FACT-JACIE)
9. CMS — Medicare Part B Drug ASP Pricing File
   Q2 2026 quarterly file, effective April 1 – June 30, 2026
10. CMS — FY 2026 IPPS Final Rule (MS-DRG 016 / 018, NTAP)
    CAR-T DRG assignments and add-on payment policy
11. CMS — CY 2026 OPPS Final Rule (CAR-T outpatient APC)
    Outpatient CAR-T APC assignment and rate
12. CMS NCD 110.24 — Chimeric Antigen Receptor (CAR) T-cell Therapy
    National Coverage Determination for CAR-T
13. NCCN B-Cell Lymphomas Guidelines
    DLBCL, LBCL, and FL CAR-T recommendations (Yescarta Category 1 for 2L)
14. Gilead Advancing Access Patient Assistance
    Patient assistance program covering Yescarta for uninsured and underinsured patients
15. FDA National Drug Code Directory

About this page

We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding, MS-DRG/APC, and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 22, 2026 — Initial publication. ASP data: Q2 2026 (live-bound to CMS file). FY 2026 IPPS Final Rule referenced for MS-DRG 016/018 and NTAP status. Multi-stage CAR-T workflow (apheresis through CRS) documented end-to-end. FACT accreditation and YESCARTA REMS gate emphasized as #1 denial driver. CD19 CAR-T class disambiguation (Yescarta vs Kymriah vs Tecartus vs Breyanzi, plus BCMA-class Abecma and Carvykti) included for code-selection accuracy. ZUMA-7 2L LBCL positioning and timing documentation emphasized as #1 PA denial cause in the 2L setting.

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. DRG and APC content is read directly from the current IPPS and OPPS Final Rules. Payer policies are read directly from each payer's published cellular therapy / oncology coverage documents. Indication and dosing are verified against the current FDA Yescarta label revision. REMS program details are verified through Kite Pharma materials. Pivotal trial evidence is cited from peer-reviewed publications (NEJM, Lancet Oncology). We do not paraphrase from billing-software vendor blogs.